- Stocks
- Healthcare
- NASDAQ: HZNP

Price (delayed)

$87.93

Market cap

$19.76B

P/E Ratio

66.61

Dividend/share

N/A

EPS

$1.32

Enterprise value

$21.53B

Sector: Healthcare

Industry: Drug Manufacturers - General

HZNP's gross profit has soared by 64% year-on-year

Horizon Therapeutics's revenue has soared by 59% YoY

The equity has soared by 76% year-on-year but it is down by 4.2% since the previous quarter

The company's debt has surged by 157% QoQ and by 90% YoY

The stock's price to earnings (P/E) is 82% more than its last 4 quarters average of 36.6

What are the main financial stats of HZNP

Market
Valuations
Earnings

Shares outstanding

224.77M

Market cap

$19.76B

Enterprise value

$21.53B

Price to earnings (P/E)

66.61

Price to book (P/B)

5.11

Price to sales (P/S)

9

EV/EBIT

67.51

EV/EBITDA

35.67

EV/Sales

9.84

Revenue

$2.19B

EBIT

$318.89M

EBITDA

$603.42M

Free cash flow

$550.77M

Per share
Balance sheet
Liquidity

EPS

$1.32

Free cash flow per share

$2.46

Book value per share

$17.21

Revenue per share

$9.77

TBVPS

$15.9

Total assets

$7.85B

Total liabilities

$3.99B

Debt

$2.58B

Equity

$3.85B

Working capital

$1.06B

Debt to equity

0.67

Current ratio

2.37

Quick ratio

1.63

Net debt/EBITDA

2.92

Margins
Efficiency
Dividend

EBITDA margin

27.6%

Gross margin

75.5%

Net margin

12.8%

Operating margin

16.1%

Return on assets

4.6%

Return on equity

8%

Return on invested capital

12.5%

Return on capital employed

4.5%

Return on sales

14.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Horizon Therapeutics stock price performed over time

Intraday

-2.17%

1 week

-7.07%

1 month

-0.86%

1 year

109.21%

YTD

20.21%

QTD

-4.47%

How have Horizon Therapeutics's revenue and profit performed over time

Revenue

$2.19B

Gross profit

$1.65B

Operating income

$352.67M

Net income

$280.04M

Gross margin

75.5%

Net margin

12.8%

The company's operating margin has surged by 99% YoY but it fell by 28% QoQ

The company's net margin has shrunk by 70% YoY and by 28% QoQ

HZNP's gross profit has soared by 64% year-on-year

Horizon Therapeutics's revenue has soared by 59% YoY

What is Horizon Therapeutics's growth rate over time

What is Horizon Therapeutics stock price valuation

P/E

66.61

P/B

5.11

P/S

9

EV/EBIT

67.51

EV/EBITDA

35.67

EV/Sales

9.84

The stock's price to earnings (P/E) is 82% more than its last 4 quarters average of 36.6

Horizon Therapeutics's EPS has plunged by 59% YoY and by 31% from the previous quarter

The equity has soared by 76% year-on-year but it is down by 4.2% since the previous quarter

HZNP's price to book (P/B) is 70% higher than its 5-year quarterly average of 3.0 and 14% higher than its last 4 quarters average of 4.5

HZNP's price to sales (P/S) is 125% more than its 5-year quarterly average of 4.0 and 11% more than its last 4 quarters average of 8.1

Horizon Therapeutics's revenue has soared by 59% YoY

How efficient is Horizon Therapeutics business performance

HZNP's ROE has plunged by 75% YoY and by 37% from the previous quarter

Horizon Therapeutics's return on assets has shrunk by 68% YoY and by 39% QoQ

HZNP's return on invested capital is down by 47% since the previous quarter

Horizon Therapeutics's ROS has decreased by 30% from the previous quarter

What is HZNP's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HZNP.

How did Horizon Therapeutics financials performed over time

The total assets is 97% more than the total liabilities

The company's total liabilities has surged by 95% QoQ and by 88% YoY

The total assets has soared by 82% YoY and by 29% from the previous quarter

The company's debt is 33% lower than its equity

The debt to equity has surged by 168% since the previous quarter and by 8% year-on-year

The company's debt has surged by 157% QoQ and by 90% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.